Trial Profile
A Phase I, Dose-Ranging Trial of the Pasteur Merieux Connaught (PMC) Oligomeric HIV-1 gp160MN/LAI-2 Vaccine Alone or Primed With Live Recombinant ALVAC-HIV (vCP205) in HIV Seronegative Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Mar 2016
Price :
$35
*
At a glance
- Drugs HIV vaccine vCP205 (Primary)
- Indications HIV infections
- Focus Adverse reactions; Proof of concept
- 04 Mar 2016 New trial record
- 11 Feb 2016 Results published in the Journal of Infectious Diseases